Advertisement

Topics

Search Results for "Blue Oval Pill With 68 Taro"

09:11 EST 8th December 2016 | BioPortfolio

Matching Channels

Blue hues

Von Willebrand's Disease

von Willebrand disease (vWD) is the most common hereditary coagulation abnormality described in humans, although it can also be acquired as a result of other medical conditions. It arises from a qua...

Matching News

Taro CEO Kal Sundaram to Return to Sun Pharma Headquarters by the End of 2016

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that its CEO, Mr. Kal Sundaram, has infor...

Taro Announces Appointment of New CEO and New Board Member Nominations

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today the appointment of Mr. Uday Baldota as Ch...

Better Sleep in the ICU: Blue Pill or Red Pill... or No Pill?

What is the best way to improve sleep in the ICU? Does pharmacologically induced sleep offer more benefit than sedation--or should we be focusing on promoting a non-drug approach? Anesthesiology

Taro Appoints New Chief Financial Officer

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the appointment of Mariano Balaguer as Vic...

Taro's CEO Kal Sundaram to return to Sun Pharma by end of 2016

Taro Pharmaceutical Industries has announced that its CEO, Kal Sundaram, has informed Taro's board of directors of his intention to step down as CEO by the end of the current calendar year. Sundaram w...

Taro Provides Results for September 30, 2016

Tuesday, November 8th 2016 at 10:32pm UTC HAWTHORNE, N.Y.–(BUSINESS WIRE)– Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financ...

Taro CEO Kal Sundaram to Return to Sun Pharma HQ

Taro Pharmaceutical announced that its CEO, Kal Sundaram, has expressed his intention to step down as CEO by the end of the year. Sundaram will return to India, to assume an executive position at Sun...

Vanda settles Fanapt patent litigation with Taro

David SalazarVanda and Taro have entered a license agreement delineating when Taro's generic of Vanda's Fanapt can enter the market.  read more

Matching PubMed Articles

Better Sleep in the Intensive Care Unit: Blue Pill or Red Pill… or No Pill?

Two-step identification of taro (Colocasia esculenta cv. Xinmaoyu) using specific psbE-petL and simple sequence repeat-sequence characterized amplified regions (SSR-SCAR) markers.

Colocasia esculenta cv. Xinmaoyu is an eddoe-type taro cultivar local to Taicang, Jiangsu Province, China; it is characterized by its pure flavor, glutinous texture, and high nutritional value. Due to...

Genetic Diversification and Dispersal of Taro (Colocasia esculenta (L.) Schott).

Taro (Colocasia esculenta (L.) Schott) is widely distributed in tropical and sub-tropical areas. However, its origin, diversification and dispersal remain unclear. While taro genetic diversity has bee...

Additivity of Nebivolol/Valsartan Single-Pill Combination Versus Other Single-Pill Combinations for Hypertension.

Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.

Zuojin Pill has been shown to inhibit the cytochrome P450 (CYP) 2D6 isoenzyme in vitro. In Chinese individuals, CYP 2D6*10 is the most common allele with reduced enzyme activity. In this study, we inv...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement